Peptide and GLP-1 dosing chart
Every compound in the library on one page: the approved dose where one exists, and the range people report using. The two columns are not equivalent, and most compounds here have no approved dose at all.
- Approved dose comes from an FDA label, or from trial or foreign-label doses where the row says so.
- Community-reported is what sellers, clinics and users say they take. It is not a recommendation, and for most compounds no human study has tested it. Tap Risks on any row for where the figure comes from and the specific risk attached to it.
- A dose from a prescriber overrides anything on this page. If you are working out syringe units, use the calculator.
| Compound and main uses | Approved dose | Community-reported (not a recommendation) |
|---|---|---|
| 5-amino-1MQ Evidence D Fat loss and "metabolic" support; Holding on to muscle while dieting | None | One widely read guide lists 250 to 500 micrograms a day Risks |
| Adamax Evidence D Focus and mental drive | None | 50 to 150 micrograms a day as a nasal spray, in short runs of about two weeks Risks |
| Adipotide Evidence D Fat loss | None | 0.5 to 1 mg under the skin once a day, with 0.5 mg described as a common starting amount Risks |
| AHK-Cu (copper tripeptide) Evidence D Thinning hair, in scalp serums; Skin firmness | None | No figure we can attribute |
| AOD-9604 Evidence B Fat loss; Joint pain, usually alongside other injections | None. Trials used 1 to 30 mg by mouth | 250 to 500 micrograms under the skin once a day, most often about 300 micrograms Risks |
| ARA-290 (cibinetide) Evidence B Nerve pain from small-fibre neuropathy; Recovery after nerve injury | None approved | 4 mg under the skin once a day Risks |
| BPC-157 Evidence C Tendon, ligament and muscle injuries; Joint pain | None | 250 to 500 micrograms once or twice a day, injected or by mouth Risks |
| BPC-157 + KPV blend Evidence D Gut complaints and inflammation | None | No figure we can attribute |
| Cagrilintide (and CagriSema) Evidence B Obesity, combined with semaglutide as CagriSema; Added to tirzepatide or retatrutide for more weight loss | None approved. Trial target: 2.4 mg a week | 0.25 mg once a week at the start, stepped up every four weeks toward 2.4 mg a week Risks |
| CagriSema (cagrilintide + semaglutide) Evidence B Obesity and type 2 diabetes; A do-it-yourself version from separate vials | None approved. Trial target: 2.4 mg of each drug a week | Users source cagrilintide and semaglutide separately and aim for the trial target of 2.4 mg of each once a week Risks |
| Cartalax Evidence D Joint and cartilage complaints | None | 2 mg a day, in courses of four to eight weeks Risks |
| Cerebrolysin Evidence B Stroke recovery, dementia and brain injury; Sharper thinking in healthy people | None | 5 to 10 mL injected into muscle Risks |
| CJC-1295 Evidence C Raising growth hormone for muscle, fat loss, sleep and recovery | None | One widely read guide lists 2 to 4 mg once a week for the DAC version, and 100 to 300 micrograms a day for the version without DAC Risks |
| CJC-1295 + ipamorelin + tesamorelin blend Evidence D Raising growth hormone for fat loss and recovery | None | No figure we can attribute |
| CJC-1295 + ipamorelin blend Evidence D Raising growth hormone for muscle, fat loss, sleep and recovery | None | 100 to 300 micrograms of each, usually at bedtime Risks |
| Cortagen Evidence D Brain and nerve "support" | None | No figure we can attribute |
| Dihexa Evidence D Memory, focus and "brain growth" | None | 5 to 40 mg a day by mouth, or 8 to 12 mg a day under the tongue Risks |
| DSIP (delta sleep-inducing peptide) Evidence C Falling asleep and staying asleep | None | 100 to 400 micrograms under the skin in the evening, in runs of two to four weeks Risks |
| Dulaglutide (Trulicity) Evidence A Type 2 diabetes; Lowering cardiovascular risk in adults with type 2 diabetes | 0.75 mg a week, raised in steps up to 4.5 mg | No figure we can attribute |
| Eloralintide Evidence B Obesity; Weight loss from research vials | None approved. Trial doses are described on this page | No figure we can attribute |
| Epitalon Evidence C "Anti-ageing" and telomere claims; Sleep and body clock | None | 5 to 10 mg a day by injection for 10 to 20 days, repeated every four to six months Risks |
| Epitalon + MOTS-c blend Evidence D "Longevity" and energy | None | No figure we can attribute |
| FGL (FG loop peptide) Evidence C Memory and thinking | None | No figure we can attribute |
| FOXO4-DRI Evidence D Clearing aged "senescent" cells for anti-ageing | None | 1 to 5 mg every three days, for one to two weeks Risks |
| GHK-Cu + BPC-157 blend Evidence D Skin and injury recovery | None | No figure we can attribute |
| GHK-Cu + KPV blend Evidence D Skin and inflammation | None | No figure we can attribute |
| GHK-Cu and the Glow stack Evidence C Skin ageing: firmness, texture, fine lines; Scars and wound healing | None | Injected: 1 to 2 mg a day, or 1 to 2.5 mg two or three times a week Risks |
| GHRP-2 and GHRP-6 Evidence C Raising growth hormone for muscle and recovery; Appetite and weight gain, mainly GHRP-6 | None | 100 to 300 micrograms per injection under the skin, up to three times a day Risks |
| GLOW blend (GHK-Cu + BPC-157 + TB-500) Evidence D Skin quality; Injury recovery | None | 1.4 to 4.2 mg of the blend per injection, which carries 1 to 3 mg of GHK-Cu and 200 to 600 micrograms each of BPC-157 and TB-500 Risks |
| Glutathione (injectable) Evidence C Skin lightening; "Detox" and antioxidant support | None | 200 to 600 mg by injection, three times a week Risks |
| Gonadorelin Evidence C Keeping testicle function and fertility while on testosterone; Restoring fertility in a rare hormone deficiency, given by pump | None for use alongside testosterone | No figure we can attribute |
| Growth hormone (HGH) Evidence A Growth hormone deficiency in children and adults, and several named growth and wasting conditions; "Anti-ageing" | Set individually against blood tests | 0.5 to 4 IU a day by injection Risks |
| HCG Evidence A Triggering ovulation in fertility treatment; Low testosterone caused by a pituitary signalling problem in men | Set by the treating specialist for each approved use | 150 to 500 IU every other day, alongside testosterone Risks |
| Hexarelin Evidence C Raising growth hormone for muscle and recovery | None | 100 to 200 micrograms under the skin, two or three times a day Risks |
| Humanin Evidence D "Longevity" and brain protection | None | 1 to 3 mg of native humanin under the skin two or three times a week, or 100 to 500 micrograms of the stronger HNG version on the same schedule Risks |
| IGF-1 LR3 Evidence D Muscle growth | None | 20 to 80 micrograms a day by injection Risks |
| Ipamorelin Evidence C Raising growth hormone for sleep, recovery and body composition | None | 100 to 300 micrograms under the skin, usually at bedtime Risks |
| Khavinson short peptides: Bronchogen, Cardiogen and seven more Evidence D "Support" for a named organ: lungs, heart, liver, prostate and so on | None | No figure we can attribute |
| Kisspeptin Evidence B Triggering egg maturation in IVF; Low sexual desire | None | 100 to 500 micrograms of kisspeptin-10, three times a week Risks |
| KLOW blend (GHK-Cu + BPC-157 + TB-500 + KPV) Evidence D Skin quality; Injury recovery and inflammation | None | 1.6 to 4.8 mg of the blend per injection, which carries 1 to 3 mg of GHK-Cu and 200 to 600 micrograms each of BPC-157, TB-500 and KPV Risks |
| KPV Evidence D Gut inflammation, including inflammatory bowel disease; Inflamed skin, applied as a cream | None | 200 to 500 micrograms a day Risks |
| L-carnitine (injectable) Evidence B Carnitine deficiency, including in people on dialysis; Weight-loss injections | 10 to 20 mg per kilogram into a vein after dialysis. None for weight loss | 200 to 500 mg a day by injection Risks |
| Larazotide Evidence B Celiac disease; "Leaky gut" | None | No figure we can attribute |
| Lipo-C and Lipo-C + B12 (MIC lipotropic injections) Evidence D Weight loss, sold as a "skinny shot"; Energy | None | No figure we can attribute |
| Liraglutide (Saxenda, Victoza) Evidence A Long-term weight management; Type 2 diabetes, including lowering cardiovascular risk | Saxenda: 0.6 mg a day, raised weekly to 3 mg | No figure we can attribute |
| LL-37 (cathelicidin) Evidence C Hard-to-heal leg ulcers, applied to the wound; Infections, "biofilms" and immune support, by injection | None | 100 to 200 micrograms under the skin once a day, often five days on and two off Risks |
| Mazdutide Evidence B Weight management and type 2 diabetes; Weight loss from research vials | None in the US. Trials: 3 to 9 mg a week | 3 to 9 mg once a week Risks |
| Melanotan I (afamelanotide, Scenesse) Evidence A Erythropoietic protoporphyria, a rare light-sensitivity disorder; Tanning, using injected powder sold as Melanotan I | 16 mg implant every two months, placed by a clinician | 500 to 1,000 micrograms by injection, twice a week Risks |
| Melanotan II Evidence C Tanning; Libido and erections | None | 250 to 500 micrograms under the skin once a day for one to four weeks, then about 500 micrograms once or twice a week Risks |
| Methylene blue Evidence A Methemoglobinemia, a blood disorder; Memory, focus and energy | 1 mg per kilogram into a vein, in hospital. None for other uses | Anywhere from 0.5 to 5 mg a few times a week to 5 to 20 mg a day, by mouth Risks |
| MK-677 (ibutamoren) Evidence B Muscle gain; Sleep and appetite | None approved. Trials: 25 mg a day | 10 to 25 mg a day by mouth Risks |
| MOTS-c Evidence D Fat loss and "metabolic" health; Exercise performance | None | 5 to 10 mg under the skin two or three times a week Risks |
| N-acetyl Selank amidate Evidence D Anxiety and stress | None | No figure we can attribute |
| N-acetyl Semax amidate Evidence D Focus and mental energy | None | No figure we can attribute |
| NAD+ Evidence D Energy and fatigue, including after illness; "Anti-ageing" | None | Into muscle: 50 to 200 mg, two or three times a week. Under the skin: 50 to 100 mg. By drip: 500 to 1,000 mg over two to four hours Risks |
| Oxytocin Evidence B Starting or strengthening labour; Social difficulties in autism, as a nasal spray | Hospital drip only. None for the nasal spray | 10 to 20 IU as a nasal spray, as needed Risks |
| P21 (P021) Evidence D Memory and learning | None | 100 to 500 micrograms a day Risks |
| PE-22-28 Evidence D Low mood | None | 200 to 400 micrograms a day as a nasal spray, or 100 to 200 micrograms a day by injection Risks |
| PEG-MGF (mechano growth factor) Evidence D Muscle growth and repair | None | 200 to 400 micrograms per injection, two or three times a week Risks |
| Pentosan polysulfate (Elmiron) Evidence A Bladder pain from interstitial cystitis; Osteoarthritis, as injections | See the label dose below | No figure we can attribute |
| Pinealon Evidence D Memory, thinking and sleep | None | 1 to 2 mg a day by injection for 10 to 20 days, or capsules of about 20 mg a day by mouth Risks |
| PNC-27 Evidence D Sold online as a cancer treatment | None | Not published |
| Progesterone Evidence A Protecting the womb lining in women taking estrogen after menopause; Absent periods (secondary amenorrhea) | 200 mg at bedtime for 12 days of each cycle, with estrogen | No figure we can attribute |
| PT-141 (bremelanotide, Vyleesi) Evidence A Low sexual desire in premenopausal women; Erectile problems and libido in men | 1.75 mg as needed, at most one dose in 24 hours and eight a month | 1.75 mg under the skin as needed, the same as the label dose Risks |
| PT-141 + oxytocin blend Evidence D Libido and arousal | None | No figure we can attribute |
| Rapamycin (sirolimus) Evidence B Preventing kidney transplant rejection; Lymphangioleiomyomatosis, a rare lung disease | Label doses are for transplant and lung disease. Longevity trial: 5 or 10 mg once a week | No figure we can attribute |
| Retatrutide Evidence B Obesity and weight-related conditions; Type 2 diabetes | None approved. Trials: 2 mg a week, stepped up to 9 or 12 mg | 0.5 to 12 mg once a week Risks |
| Retatrutide + cagrilintide blend Evidence D Maximum weight loss | None | Users start cagrilintide at 0.25 mg a week once retatrutide is established, and step both up over months toward 12 mg of retatrutide and 2.4 mg of cagrilintide a week Risks |
| Selank Evidence C Anxiety; Stress and focus | None | 250 to 500 micrograms a day as a nasal spray Risks |
| Semaglutide (Wegovy, Ozempic) Evidence A Long-term weight management; Type 2 diabetes | 0.25 mg a week, raised in steps to 2.4 mg (injection) | Microdosing: 0.1 to 0.25 mg once a week Risks |
| Semax Evidence C Stroke recovery and thinking problems; Focus and mental energy in healthy people | None in the US. Russian clinical practice is described below | 200 to 600 micrograms as a nasal spray, once or twice a day, in runs of 10 to 14 days Risks |
| Semax + Selank blend Evidence D Focus without anxiety | None | No figure we can attribute |
| Sermorelin Evidence B Growth hormone deficiency in children; Sleep, recovery and body composition in adults | None | 200 to 500 micrograms under the skin at night Risks |
| SLU-PP-332 Evidence D Endurance and fat loss, sold as "exercise in a pill" | None | There is no agreed figure Risks |
| SNAP-8 (acetyl octapeptide-3) Evidence C Expression lines, in creams and serums | None | No figure we can attribute |
| SS-31 (elamipretide, Forzinity) Evidence B Barth syndrome; Fatigue, "mitochondrial support" and exercise performance | 40 mg a day, for people 30 kg or heavier | 1 to 5 mg under the skin once a day is the most common report, within a wider range of 1 to 10 mg Risks |
| Survodutide Evidence B Obesity; MASH, a serious fatty liver disease | None approved. Trials: 3.6 or 6 mg a week after slow steps | 0.3 to 6 mg once a week, starting low Risks |
| TB-500 Evidence D Muscle, tendon and ligament injuries; Recovery after surgery | None | 2 to 4 mg twice a week Risks |
| Tesamorelin (Egrifta) Evidence A Excess abdominal fat in adults with HIV and lipodystrophy; Fatty liver disease | Once a day; the milligram amount depends on the formulation | 1 to 2 mg under the skin once a day Risks |
| Tesamorelin + ipamorelin blend Evidence D Belly fat and recovery | None | No figure we can attribute |
| Tesofensine Evidence B Weight loss | None approved. Trial doses are described on this page | No figure we can attribute |
| Testosterone (cypionate, enanthate) Evidence A Low testosterone with an associated medical condition; Age-related low testosterone | Cypionate: 50 to 400 mg every two to four weeks | No figure we can attribute |
| Thymalin Evidence C Immune problems; "Longevity" | None | 5 to 10 mg a day into muscle for 5 to 10 days, repeated as occasional courses Risks |
| Thymogen (Glu-Trp) Evidence C Immune support | None | No figure we can attribute |
| Thymosin alpha-1 Evidence B Hepatitis B, and as an immune booster with vaccines; General immune support, chronic infections and fatigue | None in the US. Abroad: 1.6 mg twice a week | 1.6 mg under the skin twice a week Risks |
| Thymulin Evidence D Immune support | None | 5 to 10 mg a day for one to two weeks Risks |
| Tirzepatide (Zepbound, Mounjaro) Evidence A Long-term weight management; Type 2 diabetes | 2.5 mg a week to start, then 5 to 15 mg | Microdosing: 0.5 to 2 mg once a week Risks |
| Tirzepatide + BPC-157 blend Evidence D Weight loss with fewer stomach side effects | None | No figure we can attribute |
| Vesugen Evidence D Blood vessel "support" | None | No figure we can attribute |
| Vilon (Lys-Glu) Evidence D Immune support and "anti-ageing" | None | 100 to 500 micrograms a day under the skin, or one to two capsules a day for 10 to 30 days Risks |
| VIP (vasoactive intestinal peptide, aviptadil) Evidence C Chronic inflammatory illness blamed on mould exposure, as a nasal spray; Brain fog and heat intolerance | None | 25 to 200 micrograms a day as a nasal spray Risks |
| Vitamin B12 injections (cyanocobalamin) Evidence A B12 deficiency, including pernicious anemia; Energy and weight-loss shots in people who are not deficient | See the label dose below | No figure we can attribute |
| Wolverine blend (BPC-157 + TB-500) Evidence D Tendon, ligament and muscle injuries; Recovery after surgery or hard training | None | 250 to 500 micrograms of BPC-157 a day, with 1 to 2.5 mg of TB-500 two or three times a week Risks |
This chart is a summary of the library pages as of November 18, 2026. Each compound's own page is the full and current version, with sources. Evidence grades run from A (strong human evidence) to D (little or none) and describe evidence, not safety.